Physician profile
Carol C Marks
NPI 1437133717
$2,150.41
in general payments reported to CMS, 2019-2025
12 companies · $751 in 2025
The $751 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $201 · 2023: $436 · 2024: $763 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,934 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,934.32 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528.14 | 2022-2025 | |
| Lilly USA, LLC | $390.01 | 2023-2025 | Olumiant, Ebglyss, Taltz |
| Sun Pharmaceutical Industries INC. | $366.11 | 2022-2025 | Ilumya, Blu-U, Odomzo |
| Amgen INC. | $298.60 | 2024-2025 | Otezla, Otezla |
| Ucb, INC. | $281.60 | 2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $83.61 | 2024-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $50.58 | 2022-2024 | Dupixent |
| Pfizer INC. | $47.44 | 2022-2023 | |
| Janssen Biotech, INC. | $42.39 | 2025 | Tremfya |
| Galderma Laboratories, L.P. | $31.42 | 2022-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $15.34 | 2023 | |
| Organon LLC | $15.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.